2017 Buyer’s Guide

This buyer’s guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.

FORWARD PRO Postmarket Study Will Evaluate Medtronic's CoreValve Evolut Pro TAVR System

 

September 21, 2017—Medtronic announced a new postmarket clinical study that will evaluate its CoreValve Evolut Pro transcatheter aortic valve replacement (TAVR) system in everyday clinical practice, including patients with severe symptomatic aortic stenosis at an intermediate, high, or extreme risk for open heart surgery.

The FORWARD PRO clinical study will evaluate the longer-term performance of the company's next-generation, self-expanding TAVR system, which was recently approved for commercial use in Europe and the United States.

The multicenter, prospective, single-arm FORWARD PRO study will enroll 600 patients across 35 sites in Europe. The study will evaluate safety including all-cause mortality and all stroke at 30 days, as well as clinical performance including valve hemodynamics and paravalvular regurgitation. Patients will be followed out to 5 years.

The Evolut Pro valve is built from Medtronic's Evolut R platform and is designed with an outer tissue wrap to further advance valve sealing performance. The biocompatible porcine pericardial tissue wrap, in addition to other design elements, is incorporated to address the occurrence valvular leak.

The company noted that the Evolut Pro valve showed no moderate/severe paravalvular leak (0%), high rates of survival (98.3%), and a low rate of disabling stroke (1.7%) at 30 days in data presented in March at ACC.17, the American College of Cardiology's 66th annual scientific session in Washington, DC.

Prof. Eberhard Grube, MD, Coprincipal Investigator of the FORWARD PRO study, commented in Medtronic's announcement, “We look forward to replicating the excellent clinical outcomes demonstrated by the Evolut Pro valve in a study designed to look at the valve’s longer-term real-world performance. The Evolut Pro has shown exceptional results for patients with severe aortic stenosis and we are excited to enroll our first patients into this rigorous study.”

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.